Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.
What’s next for argenx, Europe’s autoimmune breakthrough?
Background, Latest NewsOver the past few years, Belgium’s argenx has become a biotech force to be reckoned with, driven by the success of its autoimmune drug Vyvgart (efgartigimod alfa) in diseases such as generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). We caught up with CEO Karen Massey to discuss how she plans to build on this success after joining argenx in March 2023 and taking up the role of CEO at the start of this year.
Perfusion for next generation biosimilars
slider, Sponsored PublicationsPerfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.
Every process is different. Not the platform.
slider, Sponsored PublicationsFor CDMOs, flexible upstream platforms can help streamline process development while maintaining reproducibility and continuity across scales.
Newron plans heart tests to lift schizophrenia trial hold
Latest NewsItaly’s Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug’s clinical studies. The company will ask the agency to lift the hold by screening patients for hidden heart-rhythm disorders, including with genetic tests.
Alligator’s CFO takes the top job, Sensorion names finance chief and RQ Bio appoints new CMO
Latest NewsEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a CEO transition shaped by a strategic retreat, a finance hire ahead of a gene therapy trial and a medical appointment as an influenza antibody approaches the clinic.
ADC Therapeutics buys time for Zynlonta with $86.6M financing
Latest NewsSwiss biotech ADC Therapeutics has secured an $86.6 million (€77.5 million) financing agreement alongside debt and royalty deal amendments that extend its expected cash runway into 2029 and remove a potential obstacle to a takeover.
Another bad day at Zealand: Roche-partnered drug disappoints on blood sugar
Latest NewsZealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood sugar control. It’s the second positive trial readout that has failed to reassure investors in the course of a week.
Roche taps Chinese biotech Defand in reported $1B deal
Latest NewsRoche has partnered with China’s Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases, in a research and licensing agreement reportedly worth close to $1 billion (€895 million).
Argenx halts Phase 3 Sjögren’s trial, sending shares tumbling
Latest NewsArgenx is stopping its Phase 3 UNITY trial of efgartigimod in Sjögren’s disease after an interim analysis showed the study could not meet its primary endpoint. Shares fell about 18% in Euronext Brussels trading following the announcement, overshadowing positive Phase 2 results for its recently acquired celiac disease drug FB102.
Rivercell raises $25M to build an AI virtual cell
Latest NewsParis-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI models that predict how human cells respond to drugs and genetic changes.